Algorae Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Algorae Pharmaceuticals's earnings have been declining at an average annual rate of -4.2%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 58% per year.
Key information
-4.2%
Earnings growth rate
21.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -58.0% |
Return on equity | -69.5% |
Net Margin | -1,673.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Algorae Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -2 | 1 | 1 |
31 Mar 24 | 0 | -2 | 1 | 1 |
31 Dec 23 | 0 | -2 | 1 | 1 |
30 Sep 23 | 0 | -2 | 0 | 1 |
30 Jun 23 | 0 | -2 | 0 | 1 |
31 Mar 23 | 0 | -2 | 0 | 2 |
31 Dec 22 | 0 | -3 | 0 | 2 |
30 Sep 22 | 0 | -2 | 0 | 2 |
30 Jun 22 | 0 | -2 | 0 | 1 |
31 Mar 22 | 0 | -2 | 0 | 2 |
31 Dec 21 | 0 | -2 | 0 | 2 |
30 Sep 21 | 0 | -2 | 0 | 2 |
30 Jun 21 | 0 | -1 | 0 | 2 |
31 Mar 21 | 0 | -1 | 0 | 2 |
31 Dec 20 | 0 | -1 | 0 | 2 |
30 Sep 20 | 0 | -1 | 0 | 2 |
30 Jun 20 | 1 | -1 | 0 | 2 |
31 Mar 20 | 1 | -1 | 0 | 2 |
31 Dec 19 | 1 | -2 | 0 | 2 |
30 Sep 19 | 1 | -3 | 0 | 3 |
30 Jun 19 | 1 | -3 | 0 | 3 |
31 Mar 19 | 1 | -2 | 0 | 3 |
31 Dec 18 | 1 | 0 | 0 | 3 |
30 Sep 18 | 1 | 0 | 0 | 3 |
30 Jun 18 | 1 | 0 | 0 | 3 |
31 Mar 18 | 1 | -2 | 0 | 4 |
31 Dec 17 | 1 | -4 | 0 | 4 |
30 Sep 17 | 1 | -4 | 0 | 4 |
30 Jun 17 | 1 | -4 | 0 | 4 |
31 Mar 17 | 1 | -4 | 0 | 4 |
31 Dec 16 | 1 | -4 | 0 | 4 |
30 Sep 16 | 1 | -3 | 0 | 4 |
30 Jun 16 | 1 | -3 | 0 | 3 |
31 Mar 16 | 1 | -5 | 1 | 3 |
31 Dec 15 | 0 | -6 | 2 | 2 |
30 Sep 15 | 1 | -7 | 2 | 2 |
30 Jun 15 | 1 | -7 | 2 | 2 |
31 Mar 15 | 2 | -7 | 2 | 1 |
31 Dec 14 | 4 | -6 | 2 | 1 |
30 Sep 14 | 6 | -6 | 2 | 1 |
30 Jun 14 | 8 | -7 | 2 | 0 |
31 Mar 14 | 8 | -6 | 1 | 1 |
31 Dec 13 | 9 | -6 | 1 | 1 |
Quality Earnings: LVCL.F is currently unprofitable.
Growing Profit Margin: LVCL.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LVCL.F is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.
Accelerating Growth: Unable to compare LVCL.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LVCL.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: LVCL.F has a negative Return on Equity (-69.52%), as it is currently unprofitable.